Nephrocare Health Services Limited has informed the Exchange about Investor Presentation
NEPHROPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
NephroPlus, India's and Asia's largest dialysis network, reported strong FY26 results with revenue of ₹998.8 crore (up 32.2% YoY) and adjusted PAT of ₹128.3 crore (up 74.6% YoY). The company served 36,981 patients across 524 clinics in 5 countries, delivering 38.4 lakh treatments (up 16.6%). International revenue contribution increased from 31.8% to 41.8%, driven by higher-priced markets like Uzbekistan and Philippines. ROCE improved to 22.8%, reflecting operational leverage from the scaled platform. Q4 FY26 showed revenue of ₹265.6 crore (up 21.2%) with adjusted PAT of ₹35.1 crore. Management highlighted focus on consolidating India leadership, scaling international operations, and pursuing acquisitions.
The strong 32% revenue growth and 75% PAT growth demonstrate execution capability post-IPO. The improving mix towards international markets and rising revenue per treatment (₹3,384) suggest margin expansion potential. Healthy 22.8% ROCE indicates efficient capital deployment.